Survival rates من إعداد فريق مايو كلينك Cancer survival rates tell you the percentage of people who survive a certain type of cancer for a specific amount of time. Cancer statistics often use a five-year relative survival rate. This rate compares survival among people with the cancer and survival among people in the general population. Children with rhabdomyosarcoma generally have a better outlook than do teens and adults with rhabdomyosarcoma. Survival rates are based on large groups of people. Your outlook may be different based on a number of factors. These include the type of rhabdomyosarcoma you have, what treatments you receive and how well those treatments work. For children and young adults, estimated five-year survival by risk group is: Very low risk. More than 90%. Low risk. About 70% to more than 90%. Intermediate risk. About 50% to 70%. High risk. About 20% to 30%. Rhabdomyosarcoma recurrence five or more years after successful treatment is uncommon, but it can happen. Stage 4 survival Stage 4 rhabdomyosarcoma means the cancer has spread to distant parts of the body. Many people with stage 4 rhabdomyosarcoma are in the high-risk group. High-risk rhabdomyosarcoma usually has a five-year survival rate of about 20% to 30%. The survival rates can give you a general idea of how people with rhabdomyosarcoma have done over time. But they cannot show exactly what will happen for one person. Your healthcare team can explain what the survival statistics may mean for your specific situation. طلب تحديد موعد التشخيص والعلاج 24/12/2025 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة Living with الساركوما العضلية المخططة? Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community. Sarcoma Discussions Chondrosarcoma: Anyone have above the knee amputation? 3 Replies Sun, Oct 18, 2026 chevron-right Diagnosed with sarcoma? Let's share 1111 Replies Sat, Oct 17, 2026 chevron-right What treatments did you have for angiosarcoma? 17 Replies Fri, Oct 16, 2026 chevron-right See more discussions إظهار المَراجع Goldblum JR, et al. Rhabdomyosarcoma. In: Enzinger and Weiss's Soft Tissue Tumors. 7th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed July 31, 2023. Rhabdomyosarcoma. Cancer.Net. https://www.cancer.net/cancer-types/rhabdomyosarcoma-childhood. Accessed Aug. 2, 2023. Soft tissue sarcoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464. Accessed July 31, 2023. Niederhuber JE, et al., eds. Pediatric solid tumors. In: Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed July 31, 2023. Childhood rhabdomyosarcoma treatment (PDQ). National Cancer Institute. https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq. Accessed Aug. 2, 2023. Ami TR. Allscripts EPSi. Mayo Clinic. April 5, 2023. NCCN member institutions. National Comprehensive Cancer Network. https://www.nccn.org/members/network.aspx. Accessed Aug. 2, 2023. Locations. Children's Oncology Group. https://www.childrensoncologygroup.org/index.php/locations. Accessed Aug. 2, 2023. الساركوما العضلية المخططةالأعراضوالأسبابالتشخيصوالعلاجالأطباءوالأقسامالرعاية فيMayoClinic CON-20248513 الأمراض والحالات الساركوما العضلية المخططة